Mechanisms of blood-induced joint disease in hemophilia and potential novel targets for interventions

Hemophilic joint disease, or blood-induced joint disease (BIJD), a rises from recurrent or even subclinical hemarthroses that initiate a cascade of iron-driven synovial and cartilage pathology. When blood enters the joint, iron deposition triggers oxidative stress, generating IL-1β and TNF-α-mediated inflammation, synovial hyperplasia, and persistent angiogenesis. Foundational studies show that iron exposure activates oncogene-like programs in synovial fibroblasts, including c-MYC and MDM2, promoting proliferative and anti-apoptotic behavior that contributes to villous hypertrophy. Contemporary single-cell analyses reveal heterogeneous fibroblast, endothelial, and mast cell populations that orchestrate iron handling, inflammation, and vascular remodeling. Notably, endothelial cells exposed to repeated bleeding exhibit ferroptosis signatures, increased permeability, and signaling through ferritin light chain (FTL) to SCARA5-positive fibroblasts, forming an iron-responsive stromal circuit that may predispose joints to rebleeding. Macrophages propagate osteochondral injury through iRhom2/ADAM17-dependent TNF-α shedding, linking hemarthrosis to bone loss. Cartilage injury occurs rapidly: even short exposures to low concentrations of blood induce irreversible chondrocyte apoptosis, reduced proteoglycan synthesis, and matrix degradation driven by ROS and iron. Recent discoveries identify TNXB-AKT signaling as a critical cartilage-protective pathway lost in hemophilic arthropathy. Despite advances in systemic and non-factor therapies, joint bleeding and arthropathy persist, highlighting the need for mechanism-based interventions beyond hemostasis. Potential targets include iron/ROS modulation, endothelial ferroptosis inhibition, mast-cell stabilization, TNF-α pathway blockade, fibroblast state reprogramming, and activation of AKT-mediated cartilage survival pathways. An integrated model positions hemarthrosis as the initiating event and iron-centered inflammatory amplification as the driver of chronic joint degeneration, underscoring opportunities for joint-directed therapeutic innovation.